[1] |
Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007; 22:788-793.
doi: 10.1111/jgh.2007.22.issue-6 |
[2] | Lazarus JV, Mark HE, Anstee QM, Arab JP, Batterham RL, Castera L, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2022; 19:60-78. |
[3] |
Majumdar A, Verbeek J, Tsochatzis EJCoip. Non-alcoholic fatty liver disease: Current therapeutic options. Curr Opin Pharmacol 2021; 61:98-105.
doi: 10.1016/j.coph.2021.09.007 pmid: 34688168 |
[4] |
Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45:846-854.
doi: 10.1002/hep.21496 pmid: 17393509 |
[5] |
Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145:782-9.e4.
doi: 10.1053/j.gastro.2013.06.057 pmid: 23860502 |
[6] |
Gu J, Liu S, Du S, Zhang Q, Xiao J, Dong Q, et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis. Eur Radiol 2019; 29:3564-3573.
doi: 10.1007/s00330-019-06072-4 pmid: 30899974 |
[7] | Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology 2019 ;156(5):1264-81.e4. |
[8] |
Paige JS, Bernstein GS, Heba E, Costa EAC, Fereirra M, Wolfson T, et al. A pilot comparative study of quantitative ultrasound, conventional ultrasound, and MRI for predicting histology-determined steatosis grade in adult nonalcoholic fatty liver disease. AJR Am J Roentgenol 2017; 208:W168-W177.
doi: 10.2214/AJR.16.16726 |
[9] |
Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol 2009; 51:1061-1067.
doi: 10.1016/j.jhep.2009.09.001 pmid: 19846234 |
[10] | van Werven JR, Marsman HA, Nederveen AJ, van Gulik TM, et al. Smits NJ, ten Kate FJ, Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology 2010; 256:159-168. |
[11] | Ferraioli G, Kumar V, Ozturk A, Nam K, de Korte CL, Barr RG.US Attenuation for Liver Fat Quantification: An AIUM-RSNA QIBA Pulse-Echo Quantitative Ultrasound Initiative. Radiology 2022: 210736. |
[12] |
Fujiwara Y, Kuroda H, Abe T, Ishida K, Oguri T, Noguchi S, et al. The B-mode image-guided ultrasound attenuation parameter accurately detects hepatic steatosis in chronic liver disease. Ultrasound Med Biol 2018; 44:2223-2232.
doi: S0301-5629(18)30272-2 pmid: 30077415 |
[13] |
Imajo K, Toyoda H, Yasuda S, Suzuki Y, Sugimoto K, Kuroda H, et al. Utility of ultrasound-guided attenuation parameter for grading steatosis with reference to MRI-PDFF in a large cohort. Clin Gastroenterol Hepatol 2022; 20:2533-2541.
doi: 10.1016/j.cgh.2021.11.003 |
[14] | Bende F, Sporea I, Șirli R, Bâldea V, Lazăr A, Lupușoru R, et al. Ultrasound-guided Attenuation Parameter (UGAP) for the quantification of liver steatosis using the Controlled Attenuation Parameter (CAP) as the reference method. Med Ultrason 2021;23:7-14. |
[15] |
Ferraioli G, Soares Monteiro LB,. Ultrasound-based techniques for the diagnosis of liver steatosis. World J Gastroenterol 2019; 25:6053-6062.
doi: 10.3748/wjg.v25.i40.6053 |
[16] |
Kuroda H, Fujiwara Y, Abe T, Nagasawa T, Oguri T, Noguchi S, et al. Two-dimensional shear wave elastography and ultrasound-guided attenuation parameter for progressive non-alcoholic steatohepatitis. PloS one 2021; 16:e0249493.
doi: 10.1371/journal.pone.0249493 |
[17] |
Papatheodoridi M, Cholongitas E. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): current concepts. Curr Pharm Des 2018; 24:4574-4586.
doi: 10.2174/1381612825666190117102111 |
[18] |
Pang Q, Zhang JY, Song SD, Qu K, Xu XS, Liu SS, et al. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. World J Gastroenterol 2015; 21:1650-1662.
doi: 10.3748/wjg.v21.i5.1650 |
[19] |
Aune D, Sen A, Norat T, Janszky I, Romundstad P, Tonstad S, et al. Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies. Circulation 2016; 133:639-649.
doi: 10.1161/CIRCULATIONAHA.115.016801 pmid: 26746176 |
[20] | Huang H, Wang J, Xu L, Miao M, Xu C. Association between high-density lipoprotein cholesterol to apolipoprotein A-I ratio and nonalcoholic fatty liver disease: a cross-sectional study. Int J Endocrinol 2021; 2021:6676526. |
[21] |
Fan N, Peng L, Xia Z, Zhang L, Song Z, Wang Y, et al. Triglycerides to high-density lipoprotein cholesterol ratio as a surrogate for nonalcoholic fatty liver disease: a cross-sectional study. Lipids Health Dis 2019; 18:39.
doi: 10.1186/s12944-019-0986-7 pmid: 30711017 |
[22] |
Fukuda Y, Hashimoto Y, Hamaguchi M, Fukuda T, Nakamura N, Ohbora A, et al. Triglycerides to high-density lipoprotein cholesterol ratio is an independent predictor of incident fatty liver; a population-based cohort study. Liver Int 2016; 36:713-720.
doi: 10.1111/liv.12977 pmid: 26444696 |
No related articles found! |
|